Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | KIF5B | P33176 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 3/20 | 0.51 |
| ▸ | FBP1 | P09467 | 2/20 | 0.51 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2164707 | 0.90 | SRC (0.55) | EGFRKDRRETKIF5BSRC | |
| SCHEMBL2163510 | 0.89 | SRC (0.54) | EGFRKDRRETKIF5BSRC | |
| SCHEMBL2164281 | 0.87 | KDR (0.49) | EGFRKDRRETKIF5BSRC | |
| SCHEMBL2164488 | 0.86 | SRC (0.51) | EGFRKDRSRCFBP1EPHA2 | |
| SCHEMBL2165397 | 0.84 | EGFR (0.60) | EGFRKDRRETSRCFBP1 | |
| SCHEMBL2164111 | 0.83 | SLC2A1 (0.55) | EGFRKDRRETSRCLCK | |
| SCHEMBL2164278 | 0.83 | KDR (0.45) | EGFRKDRRETKIF5BSRC | |
| SCHEMBL2164641 | 0.82 | FBP1 (0.69) | EGFRKDRFBP1EPHB4 | |
| SCHEMBL2164632 | 0.82 | EGFR (0.51) | EGFRKDRRETKIF5BFBP1 | |
| SCHEMBL2163779 | 0.82 | KDR (0.61) | EGFRKDRSRCFBP1EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349835-B2 | Aromatic ring fused triazine derivatives and uses thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2013-01-08 | — | — | US | claimed |
| US-20110183972-A1 | AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2011-07-28 | — | — | US | claimed |
| EP-2251332-A1 | THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF | Shenyang Pharmaceutical University (CN) | 2010-11-17 | — | — | EP | claimed |
| US-8349835-B2 | Aromatic ring fused triazine derivatives and uses thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2013-01-08 | — | — | US | disclosed |
| US-20110183972-A1 | AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2011-07-28 | — | — | US | disclosed |
| EP-2251332-A1 | THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF | Shenyang Pharmaceutical University (CN) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183972-A1 | AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF | KDR, FLT1, FLT4 | EGFR 8/4885KDR 1/4885RET 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.